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Sucrose gradient analysis of chick acetylchohne receptor (AChR) a7 subunits expressed in oocytes indicates that they form pharmacologically active 
homomers of the same size as native a7 AChRs. a size compatible with a complex of five a7 subunits. By immunoisolatmg the [“Slmethionine- 
labeled a7 subunits we also demonstrate that they do not appear to assemble with endogenous Xenopus AChR subunits Pharmacological 
characterization of detergent-solubilized brain a7 AChRs and a7 homomers reveals that they have similar but nonidentical properties. The 
pharmacological difference is most accentuated for cytisine (-50-fold). Thus, at least in El8 chicken bram, most or all of the native a7 AChRs do 
not appear to be homomeric. 
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1. INTRODUCTION 
&Bungarotoxin (aBgt) is a potent antagonist of the 
well characterized muscle-type acetylcholine receptors 
(AChRs). However, aBgt also antagonizes a subset of 
neuronal AChRs, of which some subunits (a7 and ~8) 
have been cloned [1,2]. The a7 [2] and cl8 subunits (Ger- 
zanich et al., in preparation) form functional homomers 
when expressed in oocytes. The electrophysiological 
properties of the homomers formed by expressing nor- 
mal and mutated a7 subunits in oocytes have been the 
target of many recent investigations [3-71. 
The subunit composition and function of the native 
neuronal AChRs which bind aBgt are just starting to 
be dissected. Despite the long standing knowledge that 
neuronal aBgt-sensitive proteins display nicotinic char- 
acter (reviewed in [8,9]), a more detailed characteriza- 
tion of these AChRs was made possible using a7 and 
a8 subunit-specific mAbs. Using these mAbs it has been 
shown that neuronal AChRs which bind aBgt are com- 
posed of at least three subtypes i.e. those containing a7 
subunits (a7 AChRs), a8 subunits (a8 AChRs), and 
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both a7 and a8 subunits (a7la8 AChRs) [l,lO-121. 
More recently, the contrasting pharmacological proper- 
ties of the a7 AChRs and a8 AChRs immunoisolated 
from retina have been characterized (Anand et al., man- 
uscript submitted). At the protein level, while the results 
of numerous attempts to affinity purify these AChRs all 
show multiple bands on SDS-acrylamide gel electro- 
phoresis, indicating that they are likely to be made up 
of more than one subunit [13-l 71, there has not been an 
unambiguous demonstration of the total number of 
subunits or the stoichiometry in which these subunits 
associate to form the various native neuronal AChR 
subtypes which bind aBgt. At the functional level, pre- 
liminary characterization of nicotine-induced, aBgt- 
sensitive currents (presumably of a7 AChRs) from cul- 
tured rat hippocampal neurons have been reported [ 18- 
201. 
In this paper, we characterize both native brain a7 
AChRs and a7 homomers expressed in Xenopus 
oocytes. Although exogenous AChR subunits trans- 
lated in oocytes have been reported to assemble with 
endogenous Xenopus AChR subunits [21], we demon- 
strate that no additional proteins recognizable as addi- 
tional bands on SDS-acrylamide gel electrophoresis are 
associated with a7 subunits expressed in Xenopus 
oocytes. We also show that the size of the a7 homomers 
is compatible with a complex of five a7 subunits. Fur- 
thermore, we characterize in detail the pharmacological 
properties of both the a7 homomers and the immuno- 
isolated native a7 AChR subtype from chick brain. 
Comparison of their pharmacological properties reveals 
that they exhibit remarkable similarities in their affini- 
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ties for many ligands. However, differences in affinities 
for some ligands indicate that the native a7 AChR is 
most likely to be composed of more than one kind of 
subunit. 
2. MATERIALS AND METHODS 
Z 1. mAh~ 
mAbs to a7 (318) and to a8 (305) have been previously described 
[l]. The epitope for mAb 318 was mapped using synthetic peptides to 
wtthm a7 380400 [22], thus all a7 AChR and a7 homomer hgand 
bmding studies reported here were done with subunits tethered 
through their putative large cytoplasmic domain. an interaction which 
is unlikely to alter properties of the ACh bmdmg site on their extracel- 
lular surface. mAb 305 binding was found to depend on the native 
conformation of a8 [22]. The mAbs were affinity purified using protein 
G agarose. 
2.2. E.uprewon of a7 homomers m oocytes 
The a7 cDNA was cloned mto a modified SP64T expression vector 
[23] using standard DNA cloning procedures. In vitro RNA was 
synthesized using a standard protocol [23] and more recently using the 
Megascript kit (Ambion, Austin. TX). Oocytes were prepared for 
injecttons as described m [24] and injected with -15 ng of cRNA per 
oocyte. The oocytes were Incubated in semi-sterile condittons at 18°C 
in salme solution (96 mM NaCl. 2 mM KCl, 1 mM MgCIZ. 1.8 mM 
CaCI?, 5 mM HEPES, pH 7.6) containing 5% heat-inactivated horse 
serum at 18°C for 34 days before use Metabolic labeling of expressed 
a7 subunits was achieved by incubating mjected oocytes in saline 
solution containing 0.5 mCi/ml of [“‘Slmethionme (-1.000 Wmmol, 
Amersham) for 334 days. 
2.3. Pur$cation und soluhd~-_atum of AChRs.frorn ooc~fcs and chicken 
bruin 
Oocytes expressmg homomertc a7 AChRs were homogenized in 
lysts buffer (2% Trtton X-100, 50 mM NaCI, 50 mM sodium phos- 
phate (pH 7.5), 5 mM EDTA. 5 mM EGTA. 2 mM phenylmethylsul- 
fonylfluoride. 5 mM benzamidine. 5 mM iodoacetamide. I mg/ml 
heat-denatured BSA) incubated at 4°C for 30 mm. and centrifuged for 
10 mm in a mtcrofuge to clear the cellular debris. The cleared lysate 
was then used for all the assays The preparation of Triton X-lOO- 
solubilized native neuronal AChRs which bind aBgt and the method 
of immunoisolation of the native a7 AChR subtype from these ex- 
tracts have previously been described [12]. Briefly. Triton X-100 ex- 
tracts from brain were depleted of the a7/a8 and a8 AChR subtypes 
by an overnight Incubation of -7 ml of brain extract with -1 ml of mAb 
305-coupled Actigel beads (Sterogene, 5 mg/ml gel). The beads were 
then removed by brief centrifugatton The extent of depletion was then 
tested by sohd-phase RIAs using mtcrowells coated with mAb 305 m 
the presence of 50 nM [“51]aBgt All extracts used in RIAs were found 
to be depleted of > 99% of all c&containmg subtypes. 
2.4. Sucrose grudxnt .sedm~entutton u a!\~.stJ 
Aliquots (-500~1) of extracts from either chick brain or -10 oocytes 
were layered on to 1 I ml sucrose gradients (5-20%) as previously 
described [25]. and the sedimentation of AChR analyzed by [“51]aBgt 
binding (at 50 nM) to the protein complexes immunoimmobtlized on 
Immulon 4 microwells coated with mAb 318. Immunoimmobtl~zed 
[“‘Slmethionine-labeled expressed a7 subunits from all the sucrose 
gradient fractions were eluted off m sample buffer and electrophoresed 
on 10% SDS-polyacrylamide gels. The gels were then treated for 
fluorography, dried and exposed to X-ray film at -70°C for l-3 days. 
The gels were ahgned with the X-ray films. the gel slices containmg 
the a7 subunit excised, and the amount of radioactivity in the gel slice 
determined by liquid scintillation countmg 
2.5. Pharmucologlcal crssay.~ 
Pharmacological characterization of the expressed and immunoiso- 
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lated brain a7 AChRs was performed by competitive mhtbition of 
[“‘I]aBgt binding by various ligands to AChRs immunotmmobilized 
on mAb 318-coated Immulon 4 microwells. Trtton X-100 extracts 
were added to each well in the presence of various concentration of 
the hgands and incubated for 20 mm prior to the addition of [“‘I]aBgt. 
The assays m duplicate were performed m the presence of 2 nM 
[“‘I]aBgt in a total volume of 100 ~1 After mcubation overnight at 
4°C. the wells were rinsed three times with -200 ~1 of PBYTween 20 
buffer and then counted m a y counter. The affinity of aBgt for the 
AChRs was also measured by similar sohd-phase RIAs except that 
increasing amounts of [“‘I]aBgt were used. Non-specific bmdmg in all 
cases was determined using wells not coated with mAbs. 
3. RESULTS 
3.1. Zmmunological evidence that expressed a7 subunits 
-form homomers 
Using sucrose gradient sedimentation analysis of a7 
subunits expressed in oocytes, we show that [“‘I]aBgt 
binding activity of both expressed a7 subunits and na- 
tive brain a7 AChRs cosediment at -10 S (Fig. 1). This 
0 
BRAIN AChR 
A 
Fig. 1. Co-sedimentation of detergent-solubthzed chick brain a7 
AChRs and [‘5S]methionme-labeled a7 homomers on sucrose gradi- 
ents. Sedimentation profiles of AChRs solubilized with Triton X-100 
on 5520% sucrose gradients were determmed by [“51]aBgt binding to 
AChRs and a7 homomers tmmunoisolated on microwells coated with 
a mAb to u.7. The top panel shows the sedimentation profile of chick 
brain aBgt AChRs. The arrows Indicate the position of Torpedo 
AChR monomers (M) and dimers (D). The bottom panel shows the 
sedimentation profile of a7 subunits expressed m oocytes. Bmding to 
the immunoimmobihzed protein was measured using 50 nM [i”I]aBgt. 
The [“Slmethtonine-labeled protein immunoimmobilized on the wells 
from the oocyte extracts was then eluted off m sample buffer and 
subjected to SDS-PAGE followed by fluorography. The expressed a7 
subunit bands thus identified were excised and the amount of 
[35S]methton~ne per fraction determined by liquid scintillation count- 
ing. The inset panel shows a fluorogram of the [?S]methionine-labeied 
protein in the lane corresponding to the peak [“‘I]aBgt binding fraction. 
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Fig 2. Bmding of [“‘I]aBgt to detergent-solubthzed brain a7 AChRs 
and a7 homomers. Binding of [“QBgt to Triton X-100 solubthzed 
AChRs was performed on AChRs tmmunoimmobthzed on Immulon 
4 microwells coated with a mAb to a7. Non-spectfic bmdmg was 
determined using wells not coated with the mAb. Each data poinr ts 
the mean of the values obtained from duplicate determinations. The 
insert shows Scatchard analysis of the data, displayed as bound/free 
(pmollpmol) vs. bound (pmol/l). The symbols at the right top corner 
of each plot shows the putative subunit composition of the a7 AChRs. 
assuming that the AChRs are pentameric and that the native a7 
AChRs have only two a7 hgand-bindmg subunits per AChR. as do 
(al)&6 and (a4)2(B2)i AChRs [25,26]. 
indicates that native a7 AChRs and cr7 homomers have 
the same basic size and shapes. Native cr7 AChRs and 
functional a7 homomers might be expected to exhibit 
the pentagonal symmetry of other members of the 
AChR gene family such as muscle @y6 AChR or neu- 
ronal (a4)2(B2)3 AChR [25,26]. The calculated protein 
molecular weight of the Torpedo a@y6 AChR mono- 
mer is 267,757 Da. In comparison, the calculated pro- 
tein molecular weight of the chicken a7 pentamer is 
272,750 Da. Thus a7 pentamers would sediment some- 
what faster than the Torpedo a,Jy6 AChR monomer, 
as is observed. 
Remarkably, metabolic labeling of the expressed a7 
protein with [35S]methionine indicates that these sub- 
units form a broad array of protein complexes of which 
only the ones assembled into homomers the size of na- 
tive AChRs are capable of binding [“‘I]olBgt. Immuno- 
isolation of the -10 S [35S]methionine-labeled protein 
complex using a mAb to ~7, followed by fractionation 
of this complex by SDS-PAGE reveals that it is made 
up of only one band of apparent molecular weight of 
- 60 kDa (sho]wn in the inset panel of Fig. 1). It has been 
reported that muscle AChR subunits expressed in 
oocytes from cRNA could form small amounts of func- 
tional AChRs by assembling with AChR subunits en- 
dogenously expressed in Xenopus oocytes [21]. but un- 
less the oocytes contribute an endogenous subunit of the 
same apparent molecular weight as ~7, these data argue 
that a7 subunits expressed in oocytes do not appear to 
assemble with other endogenously expressed subunits of 
the Xenopus AChR, but instead form homomers the size 
of native AChRs. 
3.2. Immunoisolation of native a7 AChRs from deter- 
gent-solubilized chick brain extracts 
We have previously shown that in El8 chick brain 
- 68% of all aBgt-sensitive AChRs are of the a7 AChR 
subtype, - 9% are ofthe a8 AChR subtype, and- 23% are 
of the mixed a7/a8 AChR subtype [12]. To obtain ex- 
tracts containing only a7 AChRs, we depleted Triton 
X-100 extracts of brain with a mAb to a8 coupled to 
agarose beads using an extract to mAb-bead ratio of 7: 1 
(v/v). The efficacy of depletion was then tested by solid 
phase RIAs using mAb microwells coated with a mAb 
to a8. Thus, we typically achieved > 99% depletion of 
all &containing AChRs (including the a8 AChRs and 
the a7/a8 AChRs). These depleted extracts were then 
used for all pharmacological assays. 
3.3. Scatchard analysis of [“‘I]aBgt binding to immu- 
noisolated brain a7 AChRs and a7 homomers 
Saturation binding curves shown in Fig. 2 were 
achieved by incubating increasing amounts [“*I]aBgt 
with native &7 AChRs and cr7 homomers immunoim- 
mobilized on microwells. Scatchard analysis of these 
binding curves reveals that a7 homomers bind [“*I]dBgt 
with a high affinity (Kd = 1.62 & 0.08 nM) that is nearly 
identical to that of the native a7 AChR subtype from 
chick brain (& = 1.66 ? 0.04 nM). 
3.4. Pharmacological characterization of native a7 
AChRs and a7 homomers 
Further pharmacological characterization to test the 
relative efficacies by which various cholinergic ligands 
and some atypical ligands, such as strychnine and 
atropine, inhibit [“‘I]aBgt binding to these AChRs was 
carried out using solid-phase RIAs. Fig. 3 shows the 
[“‘I]aBgt inhibition curves for a subset of all the ligands 
tested. The calculated Ki’s for all the ligands tested are 
shown in Table I. Thus the relative affinities of the 
various ligands for the a7 homomers was found to be 
clBgt > > cytisine > > nicotine > curare = strychnine 
> trimethaphan > ACh > TMA = atropine > Carb > 
Deca > TEA > Hexa. The affinities of the ligands for 
the native brain a7 AChRs, however, were found to be 
243 
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aBgt > > nicotine > curare = cytisine = strychnine > 
trimethaphan > ACh > atropine = TMA > Deca 
> Carb > Hexa > TEA. While many ligands showed 
smaller differences in affinity for the a7 homomers com- 
pared to the native a7 AChR, cytisine appeared to be 
the most discriminatory, showing nearly a SO-fold dif- 
ference in affinity (Fig. 4). 
Interestingly, both the native a7 AChR and a7 ho- 
momers appeared to be sensitive to strychnine, a glycin- 
ergic antagonist. and to atropine, a muscarinic antago- 
nist. It does not appear that strychnine or atropine have 
remarkably high affinity, but that several classic cholin- 
ergic ligands (e.g. curare or Carb) do not have remark- 
ably greater affinity, or even lower affinity (ACh). Even 
the simplest of possible ligands, TMA. has substantial 
affinity as compared to curare, carbamylcholine, 
atropine, and strychnine. It is interesting to note that 
strychnine has been reported to inhibit the function of 
rat a7 homomers [7] and of aBgt-binding AChRs on 
chick cochlear hair cells [27]. 
4. DISCUSSION 
In this study we first demonstrate that a7 subunits 
expressed in Xenopus oocytes form aBgt-binding a7 ho- 
momers that co-sediment with native brain a7 AChRs 
on sucrose gradients. The size of the homomeric AChRs 
is compatible with a pentamer of a7 subunits. Using 
[35S]methionine to metabolically label the a7 subunits, 
we also show that the a7 subunits do not appear to 
assemble with endogenously expressed .Yenopus AChR 
subunits. The observation that binding of [“‘I]aBgt 
only occurs when a7 subunits assemble in complexes of 
the size of native a7 AChRs suggests that the ability to 
bind both aBgt and small cholinergic ligands is acquired 
only after assembly of the a7 subunit into complexes of 
native stoichiometry, perhaps because the binding sites 
are formed by distinct parts of adjacent subunits. This 
contrasts with the case of muscle al subunits which can 
bind aBgt but acquire affinity for small cholinergic li- 
gands only after pairing up with either the y or 6 sub- 
units [28,29]. 
The native neuronal AChRs which bind aBgt have 
evaded detailed characterization since they were first 
detected. Here, using a7 and a8 subunit-specific mAbs, 
we isolated the detergent-solubilized a7 AChR subtype 
from chick brain extracts. Then by characterizing the 
pharmacological properties of mAb-tethered, deter- 
gent-solubilized a7 homomers and brain a7 AChRs 
under the same assay conditions, we were able to make 
a meaningful comparison of their pharmacological 
properties for the first time. 
A striking feature of this comparison is that the phar- 
macological properties of the a7 homomers are very 
similar to those of native a7 AChRs. However, the a7 
homomers show a - 50-fold higher affinity for binding 
cytisine than do the brain a7 AChRs. This feature, in 
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addition to the smaller differences observed with some 
of the other ligands, suggests that most if not all of the 
native a7 AChRs expressed in El8 chick brain do not 
exist as homomers, although it is conceivable that these 
a7 subunits might assemble into homomers at other 
times during development. While we cannot incontro- 
vertibly exclude the possibility that some of the pharma- 
cological differences observed are due to post-transla- 
tional modifications of the a7 AChR expressed in 
oocytes. this appears unlikely to be the case because at 
least for Torpedo AChRs expressed in oocytes, despite 
altered patterns of N-linked glycosylation of the sub- 
units [30], these AChRs were pharmacologically and 
functionally indistinguishable from the native Torpedo 
AChRs [3 1.321. All published accounts of purified verte- 
brate brain aBgt-binding AChRs report more than one 
band on SDS acrylamide gel electrophoresis [13-171, 
although in no case has it been proven that these com- 
ponents are additional AChR subunits. The pharmacol- 
ogical data shown here strongly support the notion that 
additional subunits co-assemble with the a7 subunits in 
the native AChR. The concentrations at which cytisine 
activates has previously been shown to be very sensitive 
to the type of structural subunits present. For example, 
co-expression of a3 andp2 subunits result in a -1 OO-fold 
greater efficacy for cytisine as compared to co-expres- 
sion of a3 and p4 subunits [33]. Thus while structural 
subunits do participate in the binding of. or indirectly 
influence the binding of, a7 subunits to at least some of 
the ligands, they appear to have a limited influence on 
the binding of many of the ligands by the native a7 
AChR. 
The neuronal a7 AChRs (the predominant brain 
aBgt-sensitive AChR subtype) exhibit several different 
pharmacological properties from the neuronal a4P2 
AChRs (the predominant brain aBgt-insensitive sub- 
Table I 
Pharmacological characterzation of a7 AChRs 
Llgand Affimty (K,, PM) 
Homomeric Bram 
Acetylchohne 24.9 t 4.7 103 + 8.7 
Atropme 148 2 52 198 + 10 
a-Bungarotoxin 0.00162 k 0.00008 0.00166 f 0.00004 
Carbamylcholine 250 f 11 580 * 205 
Curare 4.91 f 0.5 3.40 + 0.2 
Cytisine 0.0775 + 0.01 3.85 f 0.6 
Decamethonium 376 f 36 124 k 15 
Hexamethonium 891 + 174 800 f 50 
L-Nicotine 0.545 f. 0.02 1.44 f 0.24 
Strychnme 6.85 + 0.44 5.37 * 0.51 
Tetraethylammomum 521 t 64 1046 + 10 
Tetramethylammomum 999t 1.9 263 2 22 
Trlmethaphan 18 0 k 3.0 20.9 * 1.8 
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type). We find that a7 AChRs show less than IO-fold 
lower affinity for antagonists like curare and hexa- 
methonium, but 600- to 27,000-fold lower affinity for 
agonists such as nicotine, carbamylcholine. or cytisine, 
when compared to the affinities of the 014/32 AChRs [34]. 
Another interesting feature of a7 homomers is that they 
show only a small difference in apparent affinity for the 
agonist, nicotine, between their activatable state 
(E&-7.8 ,uM, Gerzanich et al.. manuscript in 
preparation) and their presumably desensitized state 
(&- 0.5 ,uM). This contrasts with a4/32 AChRs, 
which exhibit a large difference in their apparent affinity 
for nicotine between the two states with an EC:,, of -1 
,uM, for the activatable state, and a Kd of -3.9 nM [34], 
for the presumably desensitized state. At the functional 
level, it is interesting and perhaps toxicologically impor- 
tant to note the equipotency of nicotine and ACh (-1 
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Fig. 3. Pharmacological charactertzatton of detergent-solubilized 
bram a7 AChRs and a7 homomers. Pha~a~o~o~i~l characterization 
was performed by competitive inhibition of [“‘I]&gt binding by var- 
ious ligands to AChRs solubilized with Triton X-100 and then immu- 
noimmobihzed on mAb 31%coated Immulon 4 mtcrowells. Compett- 
ttve inhibition was performed in the presence of 2 nM [‘?JaBgt. 
Representative dose-response curves from one experiment are shown. 
Each data point is the mean of the values obtained from duplicate 
determmations. 
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Fig. 4. Correlation of affinities for hgands between the native brain 
c~7 AChRs and a7 homomers. A comparison of the affinities of native 
brain a7 AChRs for various ligands to that of the a7 homomers 
expressed in oocytes IS shown as a log-log plot. The -log I( (for the 
vartous hgands) of the brain d7 AChRs is plotted on the .x-axis and 
the a7 homomers is plotted on the y-axis. 
PM) for a4p2 AChRs expressed in oocytes [3.5,36] com- 
pared to the 14: 1 potency ratio of nicotine vs. ACh seen 
for a7 homomers ([2]; Gerzanich et al., manuscript in 
preparation). and the even greater (72-fold) selectivity 
of native a7 AChRs for nicotine vs. ACh (Table I). 
Cloning of AChR subunit cDNAs has expanded the 
repertoire of AChR subtypes that might be expressed in 
the central and peripheral nervous system. However, 
thus far biochemical techniques have not uniquely iden- 
tified structural subunits in cr7 AChRs and no candidate 
cDNAs have been identified for structural subunits for 
aBgt-binding AChRs. In this study, by comparing and 
contrasting the properties of the native ~17 AChRs and 
a7 homomers, we have provided pharmacological tools 
which wiil help authenticate the cloning of structural 
subunit cDNAs which should then allow the reconstitu- 
tion and study of native a7 AChRs in expression sys- 
tems devoid of other AChRs, 
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